Tag: irritable-bowel
-
Valeant adjusted profit misses estimates; FY forecast cut
(Reuters) – Valeant Pharmaceuticals International Inc reported a smaller-than-expected quarterly adjusted profit due to faltering sales of its dermatology products and irritable bowel syndrome drug, and the company cut its full-year profit and revenue forecasts. Valeant's U.S.-listed shares fell more than 10 percent in premarket trading on Tuesday. Up to Monday's close of $19.13, the…